Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Triptorelin
Drug ID BADD_D02297
Description Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
Indications and Usage Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Marketing Status approved; vet_approved
ATC Code L02AE04
DrugBank ID DB06825
KEGG ID D06247
MeSH ID D017329
PubChem ID 25074470
TTD Drug ID D03QRS
NDC Product Code 59149-006; 71161-106; 24338-150
UNII 9081Y98W2V
Synonyms Triptorelin Pamoate | Pamoate, Triptorelin | Triptorelin Embonate | Embonate, Triptorelin | CL-118532 | CL 118532 | CL118532 | Trelstar | Triptorelin | LHRH, Trp(6)- | GnRH, Trp(6)- | LHRH, Tryptophyl(6)- | D-Trp-6-LH-RH | 6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig) | Wy-42462 | Wy 42462 | Wy42462 | AY-25650 | AY 25650 | AY25650 | Decapeptyl | Decapeptyl Trimestral | Trimestral, Decapeptyl | Decapeptyl LP | Decapeptyl Depot
Chemical Information
Molecular Formula C64H82N18O13
CAS Registry Number 57773-63-4
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32) NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7 )NC(=O)C8CCC(=O)N8
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malaise08.01.01.003--
Memory impairment17.03.02.003; 19.20.01.003--
Menopausal symptoms21.02.02.002---
Metastases to spine15.09.03.007; 16.22.02.007---
Mood swings19.04.03.001---
Muscle spasms15.05.03.004--
Muscular weakness15.05.06.001; 17.05.03.005--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Neuropathy peripheral17.09.03.003---
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Ophthalmoplegia06.05.02.003; 17.17.02.005---
Orthopnoea02.11.05.010; 22.02.01.020---
Osteoarthritis15.01.04.001---
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Paralysis17.01.04.004---
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Pituitary infarction05.03.04.006; 17.08.01.027; 18.02.02.004; 24.04.06.016---
Pruritus23.03.12.001--
Purpura01.01.04.003; 23.06.01.004; 24.07.06.005--
Rash23.03.13.001---
Rhinitis11.01.13.004; 22.07.03.006--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages